Piper Sandler's View on Iovance Shares: Overweight Rating Continues

Monday, 3 June 2024, 12:58

Piper Sandler has reiterated their bullish stance on Iovance Biotherapeutics Inc. with an overweight rating. The firm maintains its target for the company's shares, indicating confidence in the stock's performance. Investors can take this as a positive signal for the potential growth of Iovance in the near future.

https://store.livarava.com/e969965b-21c2-11ef-a3fa-9d5fa15a64d8.jpg — Piper Sandler's View on Iovance Shares: Overweight Rating Continues

Piper Sandler's View on Iovance Shares

Piper Sandler has reiterated their bullish stance on Iovance Biotherapeutics Inc. with an overweight rating. The firm maintains its target for the company's shares, indicating confidence in the stock's performance.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.